TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01339611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Individual orientation (slides) during hospitalization period and telephone follow-up after discharge

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational program
Description: Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
Study: NCT06385496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT04712227

Intervention type: OTHER
Intervention: intubation
Description: intubation

Intervention type: OTHER
Intervention: mask ventilation
Description: mask ventilation
Study: NCT01683994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
Study: NCT01500226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Description: (4 X 50 mg capsule) 200 mg PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granisetron
Description: 2 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: 2 mg PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (4 X 0 mg capsules) 0 mg PO
Study: NCT06385496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study: NCT06249542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Delivery Improvement Intervention
Description: KPWA clinical leaders and clinicians in each clinic implemented all aspects of the care delivery improvement intervention, including screening, assessment, and shared decision-making followed, as appropriate, by treatment. The implementation strategy, which was refined during the pilot phase, included:~1. Identification of a clinical champion and local implementation team~2. Participatory design~3. Training of primary care providers and medical assistants~4. Use of EHR clinical decision support tools~5. Weekly facilitated local implementation team meetings~6. Performance monitoring with feedback, including monthly meetings with the local implementation team and clinic leaders~7. Learning sessions for primary care providers during implementation~8. Social worker use of an EHR registry with weekly supervision~9. Use of a video and informational handouts to shift attitudes and reduce stigma associated with unhealthy substance use
Study: NCT03989063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructions to perform a motor task (external vs. internal focus instructions)
Description: During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructions to perform a motor task (external vs. internal focus instructions)
Description: During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructions to perform a motor task (external vs. internal focus instructions)
Description: During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructions to perform a motor task (external vs. internal focus instructions)
Description: During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).
Study: NCT02615756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT04404257

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ControlRad System
Description: Cardiac Catheterization or electrophysiology implant procedures with Control Rad system device installed in the cath lab room #5.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Without ControlRad System
Description: Cardiac Catheterization or electrophysiology implant procedures in cath lab room 5 without the ControlRad system device.
Study: NCT04223154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS to the dlPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS to the dlPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
Study: NCT03756454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Description: Patients receiving Bezlotoxumab post-operatively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo
Study: NCT03557983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate is dissolved in Saline and topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is topically spread three times per day at the irradiated areas for one week.
Study: NCT02718417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given Q3W during chemotherapy phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given Q3W during chemotherapy phase
Study: NCT01455727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Control patients received usual care directed by their physician.
Study: NCT04170621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation using the FARAPULSE Endocardial Multi Ablation System
Study: NCT03991624

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cognitive assessment
Description: * MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease
Study: NCT02718417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given Q3W during chemotherapy phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Investigator choice of weekly or Q3W during chemotherapy phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Investigator choice of weekly or Q3W during chemotherapy phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Investigator choice of weekly or Q3W during chemotherapy phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given as single agent in maintenance portion Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given as single agent in maintenance portion Q2W
Study: NCT04650347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: visualized internal urethrotomy
Description: incision of a urethral stricture to treat urinary obstruction using Quanta Holmium device or Sache cold knife, 18 Fr silicon catheter was kept for 7 days following the prodecure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: visualized internal urethrotomy
Description: incision of a urethral stricture to treat urinary obstruction using Quanta Holmium device or Sache cold knife, 18 Fr silicon catheter was kept for 7 days following the prodecure.
Study: NCT03991624

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cognitive assessment
Description: * MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cognitive assessment
Description: * MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cognitive assessment
Description: * MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cognitive assessment
Description: * MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease
Study: NCT00260156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study: NCT04712227

Intervention type: OTHER
Intervention: mask ventilation
Description: mask ventilation
Study: NCT03075436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced demand-side sanitation, hygiene
Description: The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
Study: NCT00260156

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01577030

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-fat dairy
Description: Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Add 4 servings fruit
Description: Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
Study: NCT02341911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine,cisplatin
Description: Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine,carboplatin
Description: Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
Study: NCT01414530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral contraceptive
Description: ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
Study: NCT01615588

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Manuka Honey
Description: honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
Study: NCT03157011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global symptom score (GSS) questionary
Description: systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary, which allowed to grades severity of 10 digestive symptoms (absent, mild, moderate, or severe), asthenia and fever.
Study: NCT04633083

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Clinical Data: Registration of patient identity, sex and birth year, Body Mass Index, generic score EQ-5D-3L, Tampa Schaal voor kinesofobia and shoulder specific score like Constant Score, PROMS, ADLER, SST and postoperative ROM.~Imaging Data: A preoperative and postoperative CT scan and 1-year postoperative radiograph (all three part of standard clinical practice) will be obtained. This data is used to extract the bone geometries and implant position.~Movement Analysis: The subject should stand still followed by different motion tasks in the gait lab with collection of shoulder girdle kinematics and kinetics using a 14-camera VICON System.~Stereo Radiographic EOS Measurements: Every subject included in the study will undergo a stereo radiographic EOS exam while quite standing with their arm in various positions (van Andel et al., 2008) .~ROM simulation: With the developed ROM software, we will simulate the ROM of the 2 patient groups based on the available CT scan data.

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Clinical Data: Registration of patient identity, sex and birth year, Body Mass Index, generic score EQ-5D-3L, Tampa Schaal voor kinesofobia and shoulder specific score like Constant Score, PROMS, ADLER, SST and postoperative ROM.~Imaging Data: A preoperative and postoperative CT scan and 1-year postoperative radiograph (all three part of standard clinical practice) will be obtained. This data is used to extract the bone geometries and implant position.~Movement Analysis: The subject should stand still followed by different motion tasks in the gait lab with collection of shoulder girdle kinematics and kinetics using a 14-camera VICON System.~Stereo Radiographic EOS Measurements: Every subject included in the study will undergo a stereo radiographic EOS exam while quite standing with their arm in various positions (van Andel et al., 2008) .~ROM simulation: With the developed ROM software, we will simulate the ROM of the 2 patient groups based on the available CT scan data.
Study: NCT03263351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy group
Description: Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
Study: NCT03075436

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
Study: NCT01975831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
Study: NCT02627638

Intervention type: OTHER
Group type: OTHER
Intervention: Ostheopathic treatment
Description: Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
Study: NCT02557165

Intervention type: PROCEDURE
Intervention: Muscle biopsies
Description: Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
Study: NCT03991624

Intervention type: OTHER
Group type: OTHER
Intervention: episodic memory
Description: - A recognition task with a Remember/Know paradigm
Study: NCT03118895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom™ BA9™ drug-coated stent
Description: Drug-coated stent for coronary arteries
Study: NCT01431547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m\^2, and escalated for successive cohorts of participants until MTD is found
Study: NCT02355379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2 or capectitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4 or XELOX
Study: NCT01431547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
Study: NCT01043029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Aleglitazar 150 mcg po daily for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: Pioglitazone 45 mg po daily for 52 weeks
Study: NCT02197988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel 1.33% (20ml Volume)
Description: Transversus Abdominis Plane Block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% bupivicaine with 2 mcg/ml Fentanyl.
Description: Thoracic Epidural Anesthesia
Study: NCT02999360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language therapy
Description: There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Language therapy
Description: There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
Study: NCT02355379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2 or capecitabine
Study: NCT02999360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Background Music
Description: 30 minutes background music only
Study: NCT03670862

Intervention type: OTHER
Intervention: CT
Description: Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
Study: NCT03921229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-coaching
Description: Patients will meet with a tele-coach, who is a care team member, via video-calling, on a regular basis for six months to identify and address treatment adherence concern(s).
Study: NCT01784549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine